Business
Diagnos Announces Closing of Oversubscribed $4 Million Brokered Private Placement Led by Centurion One Capital
Not for distribution to United States newswire services or for dissemination in the United States...
About this update from Diagnos Inc.
[{"type":"text","content":"Diagnos Announces Closing of Oversubscribed $4 Million Brokered Private Placement Led by Centurion One Capital \n\n\n\n\n Not for distribution to United States newswire services or for dissemination in the United States.\n \n\n\n BROSSARD, Quebec, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. (“\n \n DIAGNOS\n \n ” or the “\n \n Company\n \n ”) (TSXV: ADK and OTCQB: DGNOF) is pleased to announce the successful closing of its previously announced upsized private placement (the “\n \n Offering\n \n ”) of units of the Company (the “\n \n Units\n \n ”). A total of 13,337,262 Units, including pursuant to an exercise of the over-allotment option, were sold under the Offering at a price of $0.30 per Unit (the “\n \n Issue Price\n \n ”) for aggregate gross proceeds of $4,001,178.60.\n \n\n The Offering was led by Centurion One Capital Corp. as lead agent and sole bookrunner (the “\n \n Lead Agent\n \n ”). Borden Ladner Gervais LLP acted as counsel to the Company, and MLT Aikins LLP acted as counsel to the Lead Agent in connection with the Offering.\n \n\n André Larente, President of the Company commented:\n \n \"DIAGNOS is very pleased to announce the closing of this oversubscribed financing. Centurion One Capital anchored the round and brought together an outstanding group of strategic investors. Their world-class team executed flawlessly, allowing us to capitalize on strong investor demand to complete the offering on an upsized basis. The net proceeds will support the advancement of key regulatory initiatives with Health Canada and the FDA, the acceleration of product development, and the expansion of commercial deployments. This additional capital enhances our ability to deliver long-term value to shareholders.\"\n \n\n\n Each Unit shall consist of one common share in the capital of the Company (each, a “\n \n Share\n \n ”) and one Share purchase warrant (each, a “\n \n Warrant\n \n ”). The Shares and Warrants to be issued in connection with the Offering will be subject to a statutory hold period of four (4) months and one day from the date of the closing date in accordance with applicable Canadian securities legislation, which period will end on April 6, 2026. Each Warrant shall entitle the holder thereof to purchase...